Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
94 hedge funds and large institutions have $814M invested in Akero Therapeutics in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 16 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5.3% more ownership
Funds ownership: 83.54% → 88.84% (+5.3%)
8% less funds holding
Funds holding: 102 → 94 (-8)
8% less capital invested
Capital invested by funds: $888M → $814M (-$73.9M)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
81% less call options, than puts
Call options by funds: $266K | Put options by funds: $1.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.6M |
| 3 |
Goldman Sachs
New York
|
+$5.23M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.87M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.39M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.25M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.97M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.74M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.53M |
AKRO Hedge Fund Activity: Q4 2020 in Review
94 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2020, worth a combined $814M — down 8.3% from $888M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AKRO and 8 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 38 added.
The largest buyer was State Street, adding an estimated $17M. The largest seller was Wellington Management Group, cutting an estimated $3.39M.
- 94 institutional investors held Akero Therapeutics (AKRO) as of Q4 2020, down from 102 in Q3 2020.
- Funds reported $814M of Akero Therapeutics stock for Q4 2020, down 8.3% quarter-over-quarter.
- 8 funds opened new Akero Therapeutics positions in Q4 2020 and 16 closed out, a net change of -8 holders.
- The largest Akero Therapeutics buyer in Q4 2020 was State Street, an estimated $17M added.
- The largest Akero Therapeutics seller in Q4 2020 was Wellington Management Group, an estimated $3.39M sold.
Based on aggregated 13F filings for Q4 2020.